Biogen Forecasts Gradual Launch For Life-Transforming Drug Spinraza

The biotech said it has had some early “challenges” securing reimbursement for Spinraza, which it priced at $750,000 for the first year of treatment for the rare disease spinal muscular atrophy

Biogen Inc. guided investors to expect a gradual launch of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA) during its fourth quarter sales and earnings call Jan. 26. The cautious outlook is notable because Spinraza is the first life-transforming medicine approved for the devastating rare neurodegenerative disease – not a drug entering a competitive therapeutic category.

But Biogen priced the drug at a staggering price, even by rare disease standards: $750,000 for the first year of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

 
• By 

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

 
• By 

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.